Aligos Therapeutics, INC 10-Q quarterly reports

Aligos Therapeutics reported a net loss for the quarter and six months ended June 30, 2026, with cash reserves projected to last only into Q4 2026, raising substantial doubt about its going concern status.

Aligos Therapeutics reports a reduced net loss for the nine months ended September 30, 2025, driven by a significant fair value change in warrants, while advancing its lead HBV drug into Phase 2 and exploring funding options amid a going concern warning.

Aligos Therapeutics reported a net income for Q2 2025 driven by a non-cash warrant re-measurement gain, while advancing its clinical pipeline for HBV, MASH, and coronavirus with new trial initiations and positive Phase 2a data for MASH.

Aligos Therapeutics reports a net income of $43.1 million for Q1 2025, primarily due to a significant gain from the change in fair value of common warrants, while highlighting progress in its clinical development programs.

Aligos Therapeutics, a clinical-stage biopharmaceutical company, released its third quarter 2024 financial results, highlighting progress in its clinical programs and financial position.

Aligos Therapeutics reported a net income of $5.1 million for the second quarter of 2024, a significant shift from a net loss of $18.8 million in the same period last year, while also highlighting progress in its clinical programs.

Aligos Therapeutics, a clinical-stage biopharmaceutical company, released its first quarter 2024 financial results, highlighting progress in its MASH, CHB, and coronavirus programs.